Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells

Cancer Gene Therapy volume 29, pages 1676–1685 (2022)Cite this article

Subjects

A Correction to this article was published on 03 February 2023

This article has been updated

Abstract

Inhibitory receptors (IRs), such as the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), are cell surface molecules expressed on both normal epithelial, endothelial, and hematopoietic cells and on neoplastic cells. IRs are usually used by cancer cells to inhibit immune cell functions. Thus, CEACAM1 positive tumor cells can interact homophilically with CEACAM1 expressed on T and NK cells to inhibit their antibody-dependent cell-mediated cytotoxicity (ADCC). In this study, we investigated the effect of agonistic/activating anti-CEACAM1 monoclonal antibody (mAb) on melanoma cell lines in vitro and in vivo, following our hypothesis that activation of CEACAM1 on melanoma cells by distinct mAbs may induce inhibition of cancer cell proliferation and/or their death. To address this, we established an activating anti-CEACAM1 mAb (CCM5.01) and characterized its binding to the CEACAM1 receptor. Using this mAb, we assessed the expression of CEACAM1 on four different human melanoma cell lines by western blot and flow cytometry and determined its effect on cell viability in vitro by MTT assay. Furthermore, we evaluated the mAb mechanism of action and found that binding of CEACAM1 with CCM5.01 induced SHP1 phosphorylation and p53 activation resulting in melanoma cell apoptosis. For in vivo studies, a xenograft model of melanoma was performed by injection of Mel-14 cells subcutaneously (s.c.) in SCID/Beige mice followed by intraperitoneal (i.p.) injection of CCM5.01 or of IgG1 isotype control every other day. CCM5.01 treated mice showed a slight but not significant decrease in tumor weight in comparison to the control group. Based on the obtained data, we suggest that activating CEACAM1 on melanoma cells might be a promising novel approach to fight cancers expressing this IR.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Binding characteristics of CCM5.01 and CCM5.19 mAbs.
Fig. 2: CEACAM1 activation reduces melanoma cell viability and induces apoptosis.
Fig. 3: CCM5.01 mAb binding of CEACAM1 on Mel-14 cell line induces p53 and SHP1 phosphorylation thus mediating a decrease in cell survival.
Fig. 4: Evaluation of anti-tumor efficacy of CCM5.01 mAb in Mel-14 xenografted SCID/Beige mice.

Similar content being viewed by others

Data availability

The datasets used and/or analyzed during this study are available from the corresponding author on request.

Change history

References

  1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801.

  2. Markel G, Sapir Y, Mandel I, Hakim M, Shaked R, Meilin E, et al. Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity. J Clin Oncol. 2016;34:3044.

    Article  Google Scholar 

  3. Helfrich I, Singer BB. Size matters: the functional role of the CEACAM1 isoform signature and its impact for NK cell-mediated killing in melanoma. Cancers. 2019;11:356.

  4. Singer BB, Scheffrahn I, Heymann R, Sigmundsson K, Kammerer R, Öbrink B. Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes: evidence for replacement of the short cytoplasmic domain isoform by glycosylphosphatidylinositol-linked proteins in human leukocytes. J Immunol. 2002;168:5139–46.

    Article  CAS  Google Scholar 

  5. Öbrink B. On the role of CEACAM1 in cancer. Lung Cancer. 2008;60:309–12.

    Article  Google Scholar 

  6. Klaile E, Müller MM, Schäfer MR, Clauder AK, Feer S, Heyl KA, et al. Binding of Candida albicans to human CEACAM1 and CEACAM6 modulates the inflammatory response of intestinal epithelial cells. MBio. 2017;8e02142.

  7. Javaheri A, Kruse T, Moonens K, Mejías-Luque R, Debraekeleer A, Asche CI, et al. Helicobacter pylori adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. Nat Microbiol. 2017;2:16189.

    Article  Google Scholar 

  8. Slevogt H, Zabel S, Opitz B, Hocke A, Eitel J, N’Guessan PD, et al. CEACAM1 inhibits Toll-like receptor 2–triggered antibacterial responses of human pulmonary epithelial cells. Nat Immunol. 2008;9:1270–8.

    Article  CAS  Google Scholar 

  9. Sheikh A, Tumala B, Vickers TJ, Alvarado D, Ciorba MA, Bhuiyan TR, et al. CEACAMs serve as toxin-stimulated receptors for enterotoxigenic Escherichia coli. Proc Natl Acad Sci USA. 2020;117:29055–62.

    Article  CAS  Google Scholar 

  10. van Sorge NM, Bonsor DA, Deng L, Lindahl E, Schmitt V, Lyndin M, et al. Bacterial protein domains with a novel Ig‐like fold target human CEACAM receptors. EMBO J. 2021;40:e106103.

  11. Ambrosi C, Scribano D, Sarshar M, Zagaglia C, Singer BB, Palamara AT. Acinetobacter baumannii targets human carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) for invasion of pneumocytes. mSystems. 2020;5:e00604-20.

  12. Gur C, Maalouf N, Shhadeh A, Berhani O, Singer BB, Bachrach G, et al. Fusobacterium nucleatum supresses anti-tumor immunity by activating CEACAM1. Oncoimmunology. 2019;8:e1581531.

    Article  Google Scholar 

  13. Galaski J, Shhadeh A, Umaña A, Yoo CC, Arpinati L, Isaacson B, et al. Fusobacterium nucleatum CbpF mediates inhibition of T cell function through CEACAM1 activation. Front Cell Infect Microbiol. 2021;11:692544.

  14. Miura HS, Nakagaki K, Taguchi F. N-terminal domain of the murine coronavirus receptor CEACAM1 is responsible for fusogenic activation and conformational changes of the spike protein. J Virol. 2004;78:216–23.

    Article  CAS  Google Scholar 

  15. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, et al. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol. 2002;168:2803–10.

    Article  CAS  Google Scholar 

  16. Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, et al. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther. 2012;11:1300–10.

    Article  CAS  Google Scholar 

  17. Laack E, Nikbakht H, Peters A, Kugler C, Jasiewicz Y, Edler L, et al. Expression of CEACAM1 in adenocarcinoma of the lung: a factor of independent prognostic significance. J Clin Oncol. 2002;20:4279–84.

    Article  Google Scholar 

  18. Takeuchi A, Yokoyama S, Nakamori M, Nakamura M, Ojima T, Yamaguchi S, et al. Loss of CEACAM1 is associated with poor prognosis and peritoneal dissemination of patients with gastric cancer. Sci Rep. 2019;9:12702.

    Article  Google Scholar 

  19. Rayes RF, Vourtzoumis P, Bou Rjeily M, Seth R, Bourdeau F, Giannias B, et al. Neutrophil extracellular trap–associated CEACAM1 as a putative therapeutic target to prevent metastatic progression of colon carcinoma. J Immunol. 2020;204:2285–94.

    Article  CAS  Google Scholar 

  20. Pan H, Shively JE. Carcinoembryonic antigen-related cell adhesion molecule-1 regulates granulopoiesis by inhibition of granulocyte colony-stimulating factor receptor. Immunity. 2010;33:620–31.

    Article  CAS  Google Scholar 

  21. Landolina N, Zaffran I, Smiljkovic D, Serrano-Candelas E, Schmiedel D, Friedman S, et al. Activation of Siglec-7 results in inhibition of in vitro and in vivo growth of human mast cell leukemia cells. Pharm Res. 2020;158:104682.

    Article  CAS  Google Scholar 

  22. Turner MA, Amirfakhri S, Nishino H, Lwin TM, Savides TJ, Reid TR, et al. A patient-derived orthotopic xenograft model of gastroesophageal-junction adenocarcinoma translated to the clinic by tumor-targeting fluorescent antibodies to carcinoembryonic-antigen-related cell-adhesion molecules. In Vivo 2021;35:1959–63.

    Article  Google Scholar 

  23. Hollandsworth HM, Amirfakhri S, Filemoni F, Schmitt V, Wennemuth G, Schmidt A, et al. Anti-carcinoembryonic antigen-related cell adhesion molecule antibody for fluorescence visualization of primary colon cancer and metastases in patient-derived orthotopic xenograft mouse models. Oncotarget. 2020;11:429–39.

    Article  Google Scholar 

  24. Legrand F, Landolina N, Zaffran I, Emeh RO, Chen E, Klion AD, et al. Siglec-7 on peripheral blood eosinophils: Surface expression and function. Allergy. 2019;74:1257–65.

    Article  CAS  Google Scholar 

  25. Ravindranath MH, Shen P, Habal N, Soh D, Nishimoto K, Gonzales A, et al. Does human melanoma express carcinoembryonic antigen? Anticancer Res. 2000;20:3083–92.

  26. Sappino AP, Buser R, Seguin Q, Fernet M, Lesne L, Gumy-Pause F, et al. The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage. Oncogenesis. 2012;1:e7.

  27. Morton CL, Houghton PJ. Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc. 2007;2:247–50.

  28. Ieda J, Yokoyama S, Tamura K, Takifuji K, Hotta T, Matsuda K, et al. Re-expression of CEACAM1 long cytoplasmic domain isoform is associated with invasion and migration of colorectal cancer. Int J Cancer. 2011;129:1351–61.

    Article  CAS  Google Scholar 

  29. Kiriyama S, Yokoyama S, Ueno M, Hayami S, Ieda J, Yamamoto N, et al. CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma. Ann Surg Oncol. 2014;21:505–14.

    Article  Google Scholar 

  30. Ortenberg R, Galore-Haskel G, Greenberg I, Zamlin B, Sapoznik S, Greenberg E, et al. CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia. 2014;16:451–60.

    Article  CAS  Google Scholar 

  31. Wicklein D, Otto B, Suling A, Elies E, Lüers G, Lange T, et al. CEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells. Sci Rep. 2018;8:11893.

    Article  Google Scholar 

  32. Sapoznik S, Ortenberg R, Schachter J, Markel G. CEACAM1 in malignant melanoma: a diagnostic and therapeutic target. Curr Top Med Chem. 2012;12:3–10.

    Article  CAS  Google Scholar 

  33. Xu J, Liu B, Ma S, Zhang J, Ji Y, Xu L, et al. Characterizing the tumor suppressor role of CEACAM1 in multiple myeloma. Cell Physiol Biochem. 2018;45:1631–40.

    Article  CAS  Google Scholar 

  34. Watt SM. Homophilic adhesion of human CEACAM1 involves N-terminal domain interactions: structural analysis of the binding site. Blood. 2001;98:1469–79.

    Article  CAS  Google Scholar 

  35. Tchoupa AK, Lichtenegger S, Reidl J, Hauck CR. Outer membrane protein P1 is the CEACAM-binding adhesin of Haemophilus influenzae. Mol Microbiol. 2015;98:440–55.

    Article  CAS  Google Scholar 

  36. Nagaishi T, Pao L, Lin S-H, Iijima H, Kaser A, Qiao S-W, et al. SHP1 phosphatase-dependent T cell inhibition by CEACAM1 adhesion molecule isoforms. Immunity. 2006;25:769–81.

    Article  CAS  Google Scholar 

  37. Singer BB, Scheffrahn I, Obrink B. The tumor growth-inhibiting cell adhesion molecule CEACAM1 (C-CAM) is differently expressed in proliferating and quiescent epithelial cells and regulates cell proliferation. Cancer Res. 2000;60:1236–44.

    CAS  Google Scholar 

  38. Singer BB, Scheffrahn I, Kammerer R, Suttorp N, Ergun S, Slevogt H. Deregulation of the CEACAM expression pattern causes undifferentiated cell growth in human lung adenocarcinoma cells. PLoS ONE. 2010;5:e8747.

  39. Ueshima C, Kataoka TR, Takei Y, Hirata M, Sugimoto A, Hirokawa M, et al. CEACAM1 long isoform has opposite effects on the growth of human mastocytosis and medullary thyroid carcinoma cells. Cancer Med. 2017;6:845–56.

    Article  CAS  Google Scholar 

  40. Chen Z, Chen L, Qiao S-W, Nagaishi T, Blumberg RS. Carcinoembryonic antigen-related cell adhesion molecule 1 inhibits proximal TCR signaling by targeting ZAP-70. J Immunol. 2008;180:6085–93.

    Article  CAS  Google Scholar 

  41. Bachelet I, Munitz A, Berent-Maoz B, Mankuta D, Levi-Schaffer F. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J Immunol. 2008;180:6064–9.

    Article  CAS  Google Scholar 

  42. Patel PC, Lee HSW, Ming AYK, Rath A, Deber CM, Yip CM, et al. Inside-out signaling promotes dynamic changes in the carcinoembryonic antigen-related cellular adhesion molecule 1 (CEACAM1) oligomeric state to control its cell adhesion properties. J Biol Chem. 2013;288:29654–69.

    Article  CAS  Google Scholar 

  43. Kim WM, Huang Y-H, Gandhi A, Blumberg RS. CEACAM1 structure and function in immunity and its therapeutic implications. Semin Immunol. 2019;42:101296.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Ofra Moshel, PhD (The Core Research Facility, The Institute of Drug Research, The Hebrew University of Jerusalem) who provided advice and technical help for FC and MST experiments and analyses.

Funding

This work was partially funded by grants from Aimwell Charitable Trust (UK), INTEGRA holdings, the Israel Cancer Association (No. 20210024) to FL-S, and the Israeli Scholarship Education Foundation (ISEF) to IZ.

Author information

Author notes

  1. These authors contributed equally: Bernhard B. Singer, Francesca Levi-Schaffer.

Authors and Affiliations

  1. Pharmacology & Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel

    Ilan Zaffran, Nadine Landolina, Pratibha Gaur & Francesca Levi-Schaffer

  2. Center for Proteomics, Faculty of Medicine, University of Rijeka, Rijeka, Croatia

    Tihana Lenac Rovis & Stipan Jonjic

  3. The Lautenberg Center for General and Tumor Immunology, The Hebrew University Hadassah Medical School, IMRIC, Jerusalem, Israel

    Ofer Mandelboim

  4. Institute of Anatomy, Medical Faculty, University Duisburg-Essen, Essen, Germany

    Bernhard B. Singer

Authors
  1. Ilan Zaffran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nadine Landolina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pratibha Gaur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tihana Lenac Rovis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stipan Jonjic
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ofer Mandelboim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bernhard B. Singer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francesca Levi-Schaffer
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Designing research studies: FL-S. Conducting experiments: IZ, NL, PG, TLR. Acquiring data: IZ, NL, TLR, SJ, BBS. Analyzing data: IZ, NL, PG, TLR, SJ, BBS, FL-S. Providing reagents: OM, SJ, BBS, FL-S. Writing the manuscript: IZ, FL-S, BBS. Revising the manuscript: IZ, BBS, FL-S.

Corresponding author

Correspondence to Francesca Levi-Schaffer.

Ethics declarations

Competing interests

The authors declare no competing interests.

Consent for publication

All authors have read and consented to the manuscript’s publication.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zaffran, I., Landolina, N., Gaur, P. et al. Activation of CEACAM1 with an agonistic monoclonal antibody results in inhibition of melanoma cells. Cancer Gene Ther 29, 1676–1685 (2022). https://doi.org/10.1038/s41417-022-00486-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-022-00486-x

Search

Advanced search

Quick links